Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...

MUMBAI: The tally of Guillain Barre Syndrome (GBS) cases in Maharashtra has reached 189, while the first GBS-suspected patient from Andheri-East was detect ...

Michael Klim's new love with founder of Almost Real and Snaaps, Michelle Owen, is about moments, memories and the magic of shared adventures.

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...

SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...

Severe cases of Guillain-Barr syndrome (GBS) can result in near-total paralysis. GBS is more common in adults and males, ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s share price fell 5% on Thursday following a weaker than expected earnings announcement. The company traded as low as $21.71 and last traded at $21.38 ...

The tally of suspected Guillain-Barré syndrome (GBS) cases in the Pune region has reached 180, with the detection of seven ...